AuthorisedTherapeutic use (Phase IV)Interventional

AIR. ANTIBIOTIC THERAPY IN RESPIRATORY TRACT INFECTIONS A controlled randomized, open label, multicenter, non-inferiority trial evaluating an individualized antibiotic treatment duration based on patient clinical response, evaluated through connected devices, for suspected community acquired pneumonia in the community setting

The AIR study is about finding the best way to treat common chest infections, known as community-acquired pneumonia, with antibiotics. Researchers want to see if they can give people just enough antibiotics to get better, rather than always a standard long course. They are comparing different treatment durations based on how a patient responds to see which approach leads to recovery by day 15 after starting treatment. This is an important study because using antibiotics wisely helps make sure they keep working when we really need them, and it could help people feel better sooner with fewer side effects. It's for adults aged 18 and over.

At a glance

Status

Authorised

Phase

Therapeutic use (Phase IV)

Sponsor

Assistance Publique Hopitaux De Paris

Enrolment target

500

Start

13 Nov 2024

Community acquired pneumonia (CAP)

What is this study about?

This study, called AIR, is investigating how we use antibiotics to treat a common type of chest infection called 'community-acquired pneumonia'. This is when you get pneumonia outside of a hospital setting. The main goal is to find the most effective way to give antibiotics – specifically, to see if we can tailor the length of treatment based on how quickly a person gets better, rather than everyone taking antibiotics for a fixed amount of time.

Researchers will be looking at how well patients recover by 15 days after they start their antibiotics. They'll also check recovery at 30 days, how long people are on antibiotics for, and if there are any side effects. An important part of the study is to see if using antibiotics for a shorter, more personalised time can still help people get well without future problems, including reducing the chances of germs becoming resistant to antibiotics.

This research is really important because it helps doctors understand the best way to use antibiotics effectively. Using antibiotics wisely means they are more likely to work when we need them, and it can also help reduce the risk of side effects for patients. The study also looks at how different antibiotics affect the 'good' bacteria in our gut and airways, which is called the microbiome.

Key takeaways

The study focuses on common chest infections (pneumonia).
It aims to find the best length of antibiotic treatment.
Researchers will check how quickly patients recover.
It involves adults aged 18 and over.
The goal is to use antibiotics wisely and reduce resistance.
You can stop participating at any time.

Who may be eligible?

This study is looking for adults who have been diagnosed with community-acquired pneumonia. This is a common type of chest infection that you get outside of a hospital.

Anyone aged 18 years or older, both men and women, can potentially take part if they meet the study's health criteria.

If you have this type of chest infection and are an adult, your doctor can check if this study might be suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of community-acquired pneumonia?
Are you currently receiving antibiotic treatment for this pneumonia?
Are you willing to have your recovery monitored by the study team?

Answer every question to see your result.

What does participation involve?

If you decide to take part in the study, you would receive antibiotics for your chest infection as decided by your doctor, following the study's plan. Your progress would be carefully monitored using special 'connected devices' or other methods to see how you are responding to treatment.

You would have check-ups at different times. The main check-up for the study will be 15 days after you start your antibiotics to see if you have recovered. There will also be a follow-up at 30 days. These appointments will involve checking your symptoms and general well-being. The exact number of visits and tests will be explained fully by the study team.

Potential risks and benefits

Taking part in the study means you would receive treatment for your pneumonia, which is a potential benefit. The study aims to find the most effective and perhaps shorter way to use antibiotics, which could mean less time on medication and fewer side effects for you in the long run. As with any medication, there's always a small chance of side effects from the antibiotics, but these will be closely monitored. You are absolutely free to leave the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France

Common questions

What kind of chest infection is this study about?

It's about 'community-acquired pneumonia,' which is a chest infection you get outside of a hospital.

Will I take different antibiotics than usual?

The study uses commonly prescribed antibiotics like Ampicillin, Amoxicillin, and others, but will look at how long you take them for.

What is 'recovery at Day 15'?

It means the study team will check how well you've recovered from your pneumonia 15 days after you started your antibiotic treatment.

Why is this research important?

It helps doctors understand the best way to use antibiotics so they work well and we don't use them more than needed, reducing antibiotic resistance.

Can anyone join this study?

The study is for adults aged 18 and over who have community-acquired pneumonia.

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.